CO2023000754A2 - Composiciones y métodos para tratar la vasculopatía del aloinjerto, la enfermedad de moyamoya, el síndrome de moyamoya y la proliferación de la íntima - Google Patents
Composiciones y métodos para tratar la vasculopatía del aloinjerto, la enfermedad de moyamoya, el síndrome de moyamoya y la proliferación de la íntimaInfo
- Publication number
- CO2023000754A2 CO2023000754A2 CONC2023/0000754A CO2023000754A CO2023000754A2 CO 2023000754 A2 CO2023000754 A2 CO 2023000754A2 CO 2023000754 A CO2023000754 A CO 2023000754A CO 2023000754 A2 CO2023000754 A2 CO 2023000754A2
- Authority
- CO
- Colombia
- Prior art keywords
- moyamoya
- methods
- syndrome
- treating
- compositions
- Prior art date
Links
- 208000009433 Moyamoya Disease Diseases 0.000 title abstract 6
- 230000008069 intimal proliferation Effects 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 108010067341 ectonucleotide pyrophosphatase phosphodiesterase 1 Proteins 0.000 abstract 2
- 101001098806 Dictyostelium discoideum cGMP-specific 3',5'-cGMP phosphodiesterase 3 Proteins 0.000 abstract 1
- 108010009413 Pyrophosphatases Proteins 0.000 abstract 1
- 102000009609 Pyrophosphatases Human genes 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6815—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
- C12Y306/01—Hydrolases acting on acid anhydrides (3.6) in phosphorus-containing anhydrides (3.6.1)
- C12Y306/01009—Nucleotide diphosphatase (3.6.1.9), i.e. nucleotide-pyrophosphatase
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/04—Phosphoric diester hydrolases (3.1.4)
- C12Y301/04001—Phosphodiesterase I (3.1.4.1)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063047865P | 2020-07-02 | 2020-07-02 | |
| US202063047877P | 2020-07-02 | 2020-07-02 | |
| US202063047848P | 2020-07-02 | 2020-07-02 | |
| US202063047793P | 2020-07-02 | 2020-07-02 | |
| PCT/US2021/040356 WO2022006545A2 (en) | 2020-07-02 | 2021-07-02 | Compositions and methods for treating allograft vasculopathy, moyamoya disease, moyamoya syndrome and intimal proliferation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2023000754A2 true CO2023000754A2 (es) | 2023-02-16 |
Family
ID=79317840
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2023/0000754A CO2023000754A2 (es) | 2020-07-02 | 2023-01-24 | Composiciones y métodos para tratar la vasculopatía del aloinjerto, la enfermedad de moyamoya, el síndrome de moyamoya y la proliferación de la íntima |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20240016951A1 (enExample) |
| EP (1) | EP4175657A4 (enExample) |
| JP (1) | JP2023532732A (enExample) |
| KR (1) | KR20230048020A (enExample) |
| CN (1) | CN116322742A (enExample) |
| AU (1) | AU2021300261A1 (enExample) |
| BR (1) | BR112022026907A2 (enExample) |
| CA (1) | CA3184349A1 (enExample) |
| CO (1) | CO2023000754A2 (enExample) |
| IL (1) | IL299503A (enExample) |
| MX (1) | MX2023000247A (enExample) |
| TW (1) | TW202216186A (enExample) |
| WO (1) | WO2022006545A2 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022091048A1 (en) | 2020-10-30 | 2022-05-05 | Integral Biosciences Private Limited | Ectonucleotide pyrophosphatase-phosphodiesterase-1 (enpp1) inhibitors and uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2545080B1 (en) * | 2010-03-12 | 2017-05-10 | Alexion Pharmaceuticals, Inc. | Npp1 fusion proteins |
| PL2956163T3 (pl) * | 2013-02-13 | 2025-04-14 | Yale University | Kompozycje do leczenia patologicznego zwapnienia i kostnienia |
| EP3377105A4 (en) * | 2015-11-20 | 2019-04-24 | Yale University | COMPOSITIONS FOR THE TREATMENT OF ECTOPIC CALIBRATION DISORDERS AND METHODS THEREWITH |
| EP3471747A1 (en) * | 2016-06-16 | 2019-04-24 | Alexion Pharmaceuticals, Inc. | Methods of treating myointimal proliferation |
| WO2018119328A1 (en) * | 2016-12-22 | 2018-06-28 | Mavupharma, Inc. | Phosphodiesterase inhibitors and methods of microbial treatment |
-
2021
- 2021-07-02 CA CA3184349A patent/CA3184349A1/en active Pending
- 2021-07-02 IL IL299503A patent/IL299503A/en unknown
- 2021-07-02 AU AU2021300261A patent/AU2021300261A1/en active Pending
- 2021-07-02 WO PCT/US2021/040356 patent/WO2022006545A2/en not_active Ceased
- 2021-07-02 MX MX2023000247A patent/MX2023000247A/es unknown
- 2021-07-02 TW TW110124480A patent/TW202216186A/zh unknown
- 2021-07-02 EP EP21831757.6A patent/EP4175657A4/en active Pending
- 2021-07-02 BR BR112022026907A patent/BR112022026907A2/pt unknown
- 2021-07-02 CN CN202180055861.8A patent/CN116322742A/zh active Pending
- 2021-07-02 JP JP2022581569A patent/JP2023532732A/ja active Pending
- 2021-07-02 KR KR1020237003831A patent/KR20230048020A/ko active Pending
-
2022
- 2022-12-30 US US18/148,888 patent/US20240016951A1/en active Pending
-
2023
- 2023-01-24 CO CONC2023/0000754A patent/CO2023000754A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2023000247A (es) | 2023-06-16 |
| JP2023532732A (ja) | 2023-07-31 |
| WO2022006545A3 (en) | 2022-03-10 |
| KR20230048020A (ko) | 2023-04-10 |
| EP4175657A2 (en) | 2023-05-10 |
| US20240016951A1 (en) | 2024-01-18 |
| CN116322742A (zh) | 2023-06-23 |
| AU2021300261A1 (en) | 2023-02-02 |
| EP4175657A4 (en) | 2024-07-17 |
| TW202216186A (zh) | 2022-05-01 |
| IL299503A (en) | 2023-02-01 |
| CA3184349A1 (en) | 2022-01-06 |
| WO2022006545A2 (en) | 2022-01-06 |
| BR112022026907A2 (pt) | 2023-01-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2017000177A (es) | Nuevos anticuerpos anti-cd38 para el tratamiento del cáncer | |
| EA202190581A1 (ru) | Антисмысловые олигонуклеотиды, нацеленные на scn2a, для лечения энцефалопатии scn1a | |
| CO2023015484A2 (es) | Compuesto, composiciones y métodos para el tratamiento de trastornos | |
| CR20250325A (es) | Formulaciones inmunoconjugadas anti-cd79b estables (divisional expediente 2020-0550) | |
| MX2020012679A (es) | Compuestos de amino-pirazincarboxamida, conjugados, y usos de los mismos. | |
| MX2020007947A (es) | Inhibidores de erbb/btk. | |
| MX2018003331A (es) | Administracion de potenciadores de regulador de la conductancia transmembrana de fibrosis quistica (cftr) deuterados. | |
| MX2026002454A (es) | Formulaciones en emulsion de inhibidores de multicinasa | |
| CO2022006087A2 (es) | Métodos para el tratamiento de la trombocitopenia inmunitaria mediante la administración de (r)-2-[3-[4-amino-3-(2-fluoro-4-fenoxi-fenil)pirazolo[3,4-d]pirimidin-1-il]piperidino-1-carbonil]-4-metil-4-[4-(oxetan-3-il)piperazin-1-il]pent-2-enonitrilo | |
| MX2020013120A (es) | Tratamiento terapéutico de cánceres de microsatélites inestables. | |
| UY40235A (es) | Compuestos de heteroarilo para el tratamiento del dolor | |
| MX2024009216A (es) | Inhibidores de ectonucleotido pirofosfatasa-fosfodiesterasa 1 (enpp1) y usos de los mismos. | |
| AR108825A1 (es) | Conjugados de anticuerpo y fármaco dirigidos contra gcc | |
| MX2020009935A (es) | Formulaciones acuosas y estables de anticuerpos anti-tau. | |
| CO2025002048A2 (es) | Anticuerpos anti monometil auristatina y fragmentos de anticuerpos | |
| MX2020011756A (es) | Compuesto farmaceutico, sales del mismo, formulaciones del mismo y metodos para hacer y usar el mismo. | |
| CL2021001397A1 (es) | Vibegrón para el tratamiento de los síntomas de la vejiga hiperactiva | |
| CL2021003442A1 (es) | Composición farmacéutica que comprende idelalisib y defactinib; y métodos para el tratamiento de cáncer. | |
| MX2023000247A (es) | Composiciones y métodos para tratar la vasculopatía del aloinjerto, la enfermedad de moyamoya, el síndrome de moyamoya y la proliferación de la íntima. | |
| AR122307A1 (es) | Agente de supresión de la proliferación celular de cáncer cd20 positivo tolerante a obinutuzumab, y composición farmacéutica, medicamento, fabricación, procedimiento de supresión de la proliferación celular, procedimiento de tratamiento, anticuerpo anti-cd20 de tipo ii, compuesto, sus combinaciones, y agente potenciador y agente inductor, relacionados con estos | |
| AR121477A1 (es) | Compuestos y métodos para el tratamiento de infecciones fúngicas | |
| CO2022018016A2 (es) | Composiciones y métodos para inhibir la proliferación de células musculares lisas vasculares | |
| MX2025004084A (es) | Uso de dosis mas altas de formulaciones de huperzina de liberacion modificada | |
| WO2021053507A9 (en) | 2-amino-s6-substituted thiopurine compounds as inhibitors of the enpp1 protein | |
| CO2022018399A2 (es) | Composiciones y métodos para tratar la enfermedad arterial periférica |